JPWO2021038097A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021038097A5 JPWO2021038097A5 JP2022512775A JP2022512775A JPWO2021038097A5 JP WO2021038097 A5 JPWO2021038097 A5 JP WO2021038097A5 JP 2022512775 A JP2022512775 A JP 2022512775A JP 2022512775 A JP2022512775 A JP 2022512775A JP WO2021038097 A5 JPWO2021038097 A5 JP WO2021038097A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cell
- composition
- antibody
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 18
- 210000004180 plasmocyte Anatomy 0.000 claims 18
- 210000003719 b-lymphocyte Anatomy 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 14
- 229940127089 cytotoxic agent Drugs 0.000 claims 14
- 239000002254 cytotoxic agent Substances 0.000 claims 14
- 231100000599 cytotoxic agent Toxicity 0.000 claims 12
- 230000000779 depleting effect Effects 0.000 claims 11
- 230000003844 B-cell-activation Effects 0.000 claims 9
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 7
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 7
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 7
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 229940125814 BTK kinase inhibitor Drugs 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 3
- 206010057244 Post viral fatigue syndrome Diseases 0.000 claims 3
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 3
- 102100029198 SLAM family member 7 Human genes 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 239000003207 proteasome inhibitor Substances 0.000 claims 3
- 229960004641 rituximab Drugs 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 2
- 229960001467 bortezomib Drugs 0.000 claims 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- QUIWHXQETADMGN-UHFFFAOYSA-N evobrutinib Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C=1C(N)=NC=NC=1NCC1CCN(C(=O)C=C)CC1 QUIWHXQETADMGN-UHFFFAOYSA-N 0.000 claims 2
- 229950003411 evobrutinib Drugs 0.000 claims 2
- 230000016784 immunoglobulin production Effects 0.000 claims 2
- 229960003347 obinutuzumab Drugs 0.000 claims 2
- 229950005751 ocrelizumab Drugs 0.000 claims 2
- 229960002450 ofatumumab Drugs 0.000 claims 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- 229950000815 veltuzumab Drugs 0.000 claims 2
- KSUDUUBCXJUFRL-SFHVURJKSA-N 6-amino-7-(4-phenoxyphenyl)-9-[(3s)-1-prop-2-enoylpiperidin-3-yl]purin-8-one Chemical compound O=C1N(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C=2C(N)=NC=NC=2N1[C@H]1CCCN(C(=O)C=C)C1 KSUDUUBCXJUFRL-SFHVURJKSA-N 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 229940124295 CD38 monoclonal antibody Drugs 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 1
- 108010064641 ONX 0912 Proteins 0.000 claims 1
- 229960003270 belimumab Drugs 0.000 claims 1
- ABSXPNGWJFAPRT-UHFFFAOYSA-N benzenesulfonic acid;n-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 ABSXPNGWJFAPRT-UHFFFAOYSA-N 0.000 claims 1
- 229960002438 carfilzomib Drugs 0.000 claims 1
- 108010021331 carfilzomib Proteins 0.000 claims 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229960002204 daratumumab Drugs 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 229950001466 delanzomib Drugs 0.000 claims 1
- SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960004137 elotuzumab Drugs 0.000 claims 1
- 229960001507 ibrutinib Drugs 0.000 claims 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229950007752 isatuximab Drugs 0.000 claims 1
- 229960003648 ixazomib Drugs 0.000 claims 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims 1
- 229950002736 marizomib Drugs 0.000 claims 1
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 claims 1
- CDOOFZZILLRUQH-GDLZYMKVSA-N n-[3-[6-[4-[(2r)-1,4-dimethyl-3-oxopiperazin-2-yl]anilino]-4-methyl-5-oxopyrazin-2-yl]-2-methylphenyl]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide Chemical compound CN1CCN(C)C(=O)[C@H]1C(C=C1)=CC=C1NC1=NC(C=2C(=C(NC(=O)C=3SC=4CCCCC=4C=3)C=CC=2)C)=CN(C)C1=O CDOOFZZILLRUQH-GDLZYMKVSA-N 0.000 claims 1
- 229950005750 oprozomib Drugs 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 claims 1
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893838P | 2019-08-30 | 2019-08-30 | |
| US62/893,838 | 2019-08-30 | ||
| PCT/EP2020/074186 WO2021038097A1 (en) | 2019-08-30 | 2020-08-31 | Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022546686A JP2022546686A (ja) | 2022-11-07 |
| JP2022546686A5 JP2022546686A5 (https=) | 2023-08-30 |
| JPWO2021038097A5 true JPWO2021038097A5 (https=) | 2023-08-30 |
Family
ID=72322444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022512775A Pending JP2022546686A (ja) | 2019-08-30 | 2020-08-31 | 形質細胞に対する抑制剤または細胞傷害剤を使用する慢性疲労症候群の処置のための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12599620B2 (https=) |
| EP (1) | EP4021457A1 (https=) |
| JP (1) | JP2022546686A (https=) |
| CN (1) | CN114980901A (https=) |
| AU (1) | AU2020339737A1 (https=) |
| CA (1) | CA3149049A1 (https=) |
| WO (1) | WO2021038097A1 (https=) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| US6713054B1 (en) * | 1998-10-07 | 2004-03-30 | Cira Technologies, Inc. | Cellular immunotherapy treatment of patients afflicted with chronic fatigue syndrome |
| NZ526720A (en) | 2000-12-28 | 2007-11-30 | Altus Pharmaceuticals Inc | Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies |
| US20040219142A1 (en) * | 2002-07-19 | 2004-11-04 | Abbott Laboratories S.A. | Treatment of skin and nail disorders using TNFalpha inhibitors |
| EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| US20110142836A1 (en) * | 2009-01-02 | 2011-06-16 | Olav Mella | B-cell depleting agents for the treatment of chronic fatigue syndrome |
| WO2016102530A1 (en) * | 2014-12-22 | 2016-06-30 | Bergen Teknologioverføring As | Cyclic phosphoric acid derivative for the treatment of chronic fatigue syndrome |
| CN108135871B (zh) * | 2015-07-23 | 2022-11-04 | 博蔚医药生物科技股份有限公司 | 阻断疾病的泛素化-蛋白酶体系统的胺萘醌化合物及医药组合物 |
| RU2018114459A (ru) * | 2015-09-21 | 2019-10-23 | Ифом Фондационе Иституто Фирк Ди Онколоджа Молеколаре | Новые стратегии лечения рака крови |
| CN108601767A (zh) | 2015-10-05 | 2018-09-28 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法 |
-
2020
- 2020-08-31 AU AU2020339737A patent/AU2020339737A1/en active Pending
- 2020-08-31 CA CA3149049A patent/CA3149049A1/en active Pending
- 2020-08-31 CN CN202080074892.3A patent/CN114980901A/zh active Pending
- 2020-08-31 US US17/638,453 patent/US12599620B2/en active Active
- 2020-08-31 JP JP2022512775A patent/JP2022546686A/ja active Pending
- 2020-08-31 EP EP20764981.5A patent/EP4021457A1/en active Pending
- 2020-08-31 WO PCT/EP2020/074186 patent/WO2021038097A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023055871A5 (https=) | ||
| US9314522B2 (en) | Antitumors combinations containing antibodies recognizing specifically CD38 and bortezomib | |
| JP2025016606A5 (https=) | ||
| CN101686971B (zh) | 用于治疗多发性骨髓瘤的药物产品及其用途 | |
| TW202327569A (zh) | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 | |
| JP2025183210A5 (https=) | ||
| JP2009518441A5 (https=) | ||
| CA2984464C (en) | Treatment for multiple myeloma (mm) | |
| RU2625222C2 (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом | |
| Wu et al. | Novel agents for chronic lymphocytic leukemia | |
| CN102065865B (zh) | 多发性骨髓瘤治疗 | |
| US20140031325A1 (en) | Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma | |
| JP2024133551A (ja) | Ｃｄ４７遮断療法およびｃｄ３８抗体の組み合わせ | |
| WO2021142257A1 (en) | Methods of treating splenomegaly | |
| Keystone | B cells in rheumatoid arthritis: from hypothesis to the clinic | |
| US20100098657A1 (en) | Method of Treating Cancer with Immunomodulatory Compounds and IgG | |
| JP2021532067A5 (https=) | ||
| JPWO2021038097A5 (https=) | ||
| CN115381939A (zh) | 治疗霍奇金淋巴瘤的药物组合物及其用途 | |
| JPWO2022177428A5 (https=) | ||
| Choi | Biologic therapies for the treatment of rheumatoid arthritis. | |
| JP2019524780A (ja) | プロテアソーム阻害剤及び抗ｃｄ３０抗体の組み合わせ | |
| WO2023073645A1 (en) | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor | |
| WO2025261276A1 (zh) | 含抗cd20抗体药物偶联物的药物组合及其治疗非霍奇金淋巴瘤的用途 | |
| JPWO2023120551A5 (https=) |